Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction.,International Journal of Impotence Research

当前位置： X-MOL 学术 › Int. J. Impot. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction.
International Journal of Impotence Research ( IF 2.8 ) Pub Date : 2019-09-03 , DOI: 10.1038/s41443-019-0186-z
Priyanka Bearelly ₁ , Elizabeth A Phillips ₂ , Shu Pan ₁ , Kevin O'Brien ₃ , Kevin Asher ₄ , Daniel Martinez ₅ , Ricardo Munarriz ₁

Affiliation

Intracavernosal injection therapy (ICI) was the first pharmacologic treatment in the management of erectile dysfunction. ICI allows for customization of medication composition and concentrations, making it a highly effective treatment with an acceptable side effect profile. The objective was to investigate the long-term results of ICI using validated and non-validated instruments. This is a retrospective, single-institution study of 105 patients (mean age 61.6 ± 11.1) patients using ICI. Mean duration of ICI was 8.4 ± 6.25 years. Pre- and post-treatment patient-reported penile rigidity were 41.1% ± 29.3 and 89.6% ± 13.6, respectively (p < 0.05). Statistical changes were also found in the pre and post International Index of Erectile Function (IIEF) scores (33.0 ± 14.4 and 60.0 ± 12.7, p < 0.05), erectile function (11.5 ± 1.3 and 27.3 ± 0.9, p < 0.05) and satisfaction domains (5.3 ± 1.5 and 8.1 ± 1.1, p < 0.05) of the IIEF. There were no statistical differences in questionnaire outcomes between difficult to treat patients (diabetes or radical prostatectomy) and the remainder of queried patients. Complications were rare and included priapism (7.1%), penile curvature (10%; <30°), bruising (7.6%), and mild penile pain (12.4%). Overall, ICI therapy is safe and effective, and compliance may be augmented by patient education, dosing customization, and cost reduction.

中文翻译：

长期腔内注射疗法：治疗效果和患者满意度。

腔内注射疗法（ICI）是治疗勃起功能障碍的首个药物治疗方法。ICI允许定制药物成分和浓度，使其成为具有可接受的副作用特征的高效治疗药物。目的是研究使用经过验证和未经验证的仪器对ICI的长期结果。这是一项回顾性，单机构研究，研究对象为使用ICI的105例患者（平均年龄61.6±11.1）。ICI的平均持续时间为8.4±6.25年。治疗前和治疗后患者报告的阴茎刚度分别为41.1％±29.3和89.6％±13.6（p <0.05）。在国际勃起功能指数（IIEF）评分（33.0±14.4和60.0±12.7，p <0.05），勃起功能（11.5±1.3和27.3±0.9，p <0.05）和IIEF的满意度域（5.3±1.5和8.1±1.1，p <0.05）。在难以治疗的患者（糖尿病或前列腺癌根治术）与其余被查询患者之间，问卷调查结果无统计学差异。并发症很少见，包括阴茎异常勃勃（7.1％），阴茎弯曲（10％； <30°），瘀伤（7.6％）和轻度阴茎痛（12.4％）。总体而言，ICI治疗是安全有效的，可以通过患者教育，定制剂量和降低成本来增强依从性。阴茎弯曲（10％; <30°），青紫（7.6％）和轻度阴茎疼痛（12.4％）。总体而言，ICI治疗是安全有效的，并且可以通过患者教育，定制剂量和降低成本来增强依从性。阴茎弯曲（10％; <30°），青紫（7.6％）和轻度阴茎疼痛（12.4％）。总体而言，ICI治疗是安全有效的，可以通过患者教育，定制剂量和降低成本来增强依从性。

更新日期：2019-09-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11